Some of the strengths in the proposed analysis are the follow-up time of 8 to 10 years and the determination of hypertension based both on the use of prescription medicine and the resting BP in mm Hg. This limits the risk of classifying a participant as false negative (eg, using antihypertensives and therefore having a resting BP below the threshold). Another strength is the randomly selected study population.